Meeting
2023 ASCO Annual Meeting
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.
Authors
David A. Braun
School of Medicine, Yale University, New Haven, CT
David A. Braun , Kelly Street , Opeyemi Jegede , Neil Ruthen , Miya Hugaboom , Nicholas R Schindler , David F. McDermott , Elizabeth R. Plimack , Jeffrey A. Sosman , Naomi B. Haas , Michael E. Hurwitz , Hans J. Hammers , Sabina Signoretti , Michael B. Atkins , Catherine J. Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4524)
DOI
10.1200/JCO.2023.41.16_suppl.4524
Abstract #
4524
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.
First Author: David A. Braun
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genomics and transcriptomics of pancreatic adenosquamous carcinoma.
First Author: Brooke Elizabeth Kania
Poster
2023 ASCO Gastrointestinal Cancers Symposium
LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).
First Author: Kai Tsugaru
Poster
2016 Genitourinary Cancers Symposium
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).
First Author: Guillermo de Velasco